Stephen Ross
Professor of Psychiatry
Data updated
Research Footprint
Stephen Ross appears in 16 tracked papers (2016–2026), most studied alongside Psilocybin, MDMA and LSD, across Depressive Disorders, Anxiety Disorders and Palliative & End-of-Life Distress.
Most-cited paper: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial (1678 citations).
Frequent co-authors: Gabrielle Agin-Liebes, Alison Bossis and Susan Mennenga.
Publication Landscape
How the 16 papers Blossom tracks for Stephen Ross line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Stephen Ross's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 16 of 16 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Stephen Ross publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Stephen Ross publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Stephen Ross is a psychiatrist and clinical researcher based at NYU Langone who has been a prominent investigator in contemporary clinical research on psilocybin-assisted psychotherapy. He trained and practised in general and addiction psychiatry and has led and co‑authored multiple clinical trials and follow‑up studies examining psilocybin for psychiatric and existential distress in patients with life‑threatening cancer, for alcohol use disorder, and for changes in religious and spiritual attitudes. His work blends controlled clinical trial methodology with detailed qualitative and phenomenological analyses of patient experience.
Ross's contributions include designing and running early-phase clinical protocols, publishing long‑term follow‑up and individual case analyses, and exploring therapeutic mechanisms such as mystical‑type and meaning‑making experiences. He has collaborated with other major figures and centres in the field (including multi‑site teams) and has emphasised careful safety monitoring, integration work, and clinical interpretation of subjective outcomes. His scholarship and public engagement have helped shape clinical and ethical conversations about the therapeutic use of psychedelic compounds in psychiatry.
Key Impact
A leading clinical investigator who has advanced the application of psilocybin-assisted psychotherapy for cancer-related existential distress and substance use disorders through influential clinical trials and qualitative studies.
Collaboration Network
29 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Stephen Ross's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Stephen Ross is associated with.
NYU Grossman School of Medicine
NYU Grossman School of Medicine is New York University's medical school and a core academic unit of NYU Langone Health. It provides MD and other medical education, conducts biomedical research, and delivers clinical care in the United States.
View stakeholder →NYU Center for Psychedelic Medicine
The NYU Langone Center for Psychedelic Medicine sits within the Department of Psychiatry at NYU Grossman School of Medicine in New York, and builds on a research group that has studied psychedelics since the early 2010s. Established in 2021 with philanthropic support, it is directed by Michael Bogenschutz, whose randomised trial of psilocybin-assisted therapy for alcohol use disorder, published in 2022, is among the most cited in the field. The centre runs translational and clinical research across psychiatry and addiction medicine, and places particular weight on training the next generation of investigators and therapists through a dedicated research fellowship. Its work spans alcohol and other substance use disorders, PTSD and related conditions.
View stakeholder →